Aubrey Capital Management Ltd Lowers Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Aubrey Capital Management Ltd reduced its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 10.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,100 shares of the biotechnology company’s stock after selling 1,800 shares during the quarter. Axon Enterprise comprises approximately 1.7% of Aubrey Capital Management Ltd’s portfolio, making the stock its 12th biggest holding. Aubrey Capital Management Ltd’s holdings in Axon Enterprise were worth $3,901,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. HB Wealth Management LLC raised its stake in shares of Axon Enterprise by 3.9% during the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 43 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Axon Enterprise by 11.0% during the fourth quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 44 shares in the last quarter. Lindbrook Capital LLC increased its stake in shares of Axon Enterprise by 43.3% in the fourth quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after buying an additional 52 shares during the period. Greenleaf Trust increased its stake in shares of Axon Enterprise by 3.6% in the third quarter. Greenleaf Trust now owns 1,540 shares of the biotechnology company’s stock worth $306,000 after buying an additional 54 shares during the period. Finally, Czech National Bank increased its stake in shares of Axon Enterprise by 0.4% in the fourth quarter. Czech National Bank now owns 12,336 shares of the biotechnology company’s stock worth $3,187,000 after buying an additional 54 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AXON shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday. StockNews.com downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. JMP Securities lifted their price target on shares of Axon Enterprise from $250.00 to $285.00 and gave the company a “market outperform” rating in a report on Tuesday, February 6th. Barclays lifted their price target on shares of Axon Enterprise from $296.00 to $308.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Robert W. Baird lifted their price target on shares of Axon Enterprise from $260.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, February 22nd. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $314.91.

Axon Enterprise Stock Up 0.6 %

Shares of AXON stock traded up $1.99 during mid-day trading on Friday, reaching $308.23. 300,741 shares of the company’s stock traded hands, compared to its average volume of 413,361. The company has a market cap of $23.26 billion, a P/E ratio of 134.01 and a beta of 0.93. The company’s 50-day moving average price is $303.45 and its 200-day moving average price is $260.90. Axon Enterprise, Inc. has a 12 month low of $175.37 and a 12 month high of $329.87. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. The company had revenue of $432.14 million for the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. On average, equities analysts expect that Axon Enterprise, Inc. will post 2.44 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.